Clinical trials: Small Cell Carcinoma of Lung
Carcinoma, Non-Small-Cell Lung
LUX Lung Special Access Scheme Australia Named Patient Use (NPU)
The program will provide early access to the investigational drug BIBW 2992 to treat patients with advanced NSCLC who have failed at least 12 weeks on erlotinib or gefitinib.
- Trial name
- NCT01209650
- Testing
- BIBW 2992
- Where
- Australia
- Sponsor
- Boehringer Ingelheim
Non-Small Cell Lung Cancer
Septum-guided Segmentectomy for 2-3 cm Clinical Stage IA3 Peripheral Non-Small Cell Lung Cancer
This is a single-center, prospective, single-arm, open-label clinical trial evaluating the efficacy and safety of septum-guided segmentectomy in patients with 2-3 cm clinical stage IA3 peripheral non-small cell lung cancer…
- Trial name
- SGS2606 (NCT07780591)
- Testing
- septum-guided anatomical segmentectomy
- Volunteers
- 100 people
- Sponsor
- Shanghai Chest Hospital
Head and Neck Cancer, Lung Cancer
Vanguard Study for Head and Neck Cancer or Non-Small Cell Lung Cancer (NSCLC) Patients
The goal of this research study is to look at how long individuals who have been treated for early stage NSCLC or HNSCC live without developing lung cancer.
- Trial name
- NCT00352391
- Testing
- Assessments
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer
ZD6474 in Treating Patients With Small Cell Lung Cancer
RATIONALE: ZD6474 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. ZD6474 may also stop the growth of small cell lung cancer by blocking blood flow to the tumor.
- Trial name
- NCT00066313
- Testing
- vandetanib, adjuvant therapy
- Where
- 21 sites in Canada
- Sponsor
- Genzyme, a Sanofi Company
Non Small Cell Lung Cancer
A Phase II Trial Measuring the Integration of Stereotactic Radiotherapy Plus Surgery in Early Non-Small Cell Lung Cancer
Stereotactic ablative radiotherapy (SABR) is a new radiation treatment that delivers high-dose, precise radiation to small tumors in 1-3 weeks of treatment. The study combines SABR and surgery to treat non-small cell lung cancer.
- Trial name
- NCT02136355
- Testing
- Stereotactic Body Radiation Therapy plus Surgery
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00807755
- Testing
- Carboplatin, Etoposide, RAD001
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of California, Davis
Brain Metastases, Adult, Brain Tumor - Metastatic
Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction
The goal of this study is to evaluate the feasibility and effectiveness of same-day radiation planning and treatment. The study will shorten the time interval between radiation planning (radiation mapping) and radiation…
- Conditions
- Brain Metastases, Adult, Brain Tumor - Metastatic, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases From Extra-cranial Solid Tumors
- Trial name
- NCT07132190
- Testing
- Linear accelerator-based stereotactic radiation for brain metastases using 0mm or 1mm PTV
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Ayal A. Aizer, MD
Non-small Cell Lung Cancer
A Trial to Evaluate the Improvement in Lung Cancer Patients Receiving Radiation With or Without Brachytherapy
A trial to improve the quality of life of patients with advanced non-small cell lung cancer (NSCLC) by evaluating the symptomatic improvements in lung cancer patients receiving external radiation with or without high dose…
- Trial name
- BRACHY (NCT01351116)
- Testing
- EBR plus HDRIB, EBR
- Where
- 8 sites in Canada
- Volunteers
- 134 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Carcinoma, Non-Small-Cell Lung
Locally Advanced NSCLC Treated With Radiochemotherapy: Phase 2 Study on the Value of a Stereotactic Boost
This is a monocentric, non-randomized, open-label, superiority phase II clinical investigation evaluating the efficacy of additional Cyberknife irradiation after a doublet of Platinum Salts-based chemotherapy and concomitant…
- Trial name
- Cybertaxcis II (NCT06627738)
- Testing
- Cyberknife irradiation
- Where
- France
- Volunteers
- 42 people
- Sponsor
- Centre Antoine Lacassagne
Non Small Cell Lung Cancer
A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients
To investigate efficacy and safety of the combination with pemetrexed plus carboplatin, followed by pemetrexed in patients with advanced nonsquamous Non Small Cell Lung Cancer (NSCLC) who receive at least one dose of the…
- Trial name
- NCT01020786
- Testing
- Pemetrexed, Carboplatin
- Where
- 16 sites in Japan
- Volunteers
- 109 people
- Sponsor
- Eli Lilly and Company
NRG1-fused Non-small Cell Lung Cancer
To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion
This is an open-label, sing-arm, phase IV clinical study. The study is designed to evaluate the efficacy of Afatinib in treatment of NRG1-fused locally advanced/metastatic non-small cell lung cancer (NSCLC), and explore the…
- Trial name
- NCT04814056
- Testing
- Afatinib Dimaleate
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai Chest Hospital
Small Cell Lung Cancer
Tempus Small Cell Lung Cancer Observational Study (Sculptor)
The study is a non-interventional evaluation of participants with extensive stage (ES) SCLC who will receive diagnostic and (where possible) post-progression tumor tissue profiling, alongside plasma ctDNA and CTC biomarker…
- Trial name
- NCT05257551
- Testing
- Observation
- Where
- 11 sites in United States
- Volunteers
- 200 people
- Sponsor
- Tempus AI
Breast Cancer, Lung Cancer
Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors
RATIONALE: Amifostine may be effective in reducing pain, numbness, tingling, and other symptoms of peripheral neuropathy. PURPOSE: This phase II trial is studying how well amifostine works in reducing pain, numbness, tingling…
- Conditions
- Breast Cancer, Lung Cancer, Neurotoxicity, Ovarian Cancer
- Trial name
- NCT00078845
- Testing
- Amifostine
- Where
- 15 sites in United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Non Small Cell Lung Cancer
20K Distributed Learning Challenge
Machine learn a predictive model from more than 20.000 non-small cell lung cancer patients from more than 5 health care providers from more than 5 countries.
- Trial name
- NCT03564457
- Testing
- No interventions will take place (observational)
- Where
- Netherlands
- Volunteers
- 20,000 people
- Sponsor
- Maastricht Radiation Oncology
SCLC, Recurrent
Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC
This is a multicenter, open-label, single-arm phase 2 study evaluating the efficacy and safety of ivonescimab combined with paclitaxel polymeric micelles in adults with recurrent or refractory small cell lung cancer after failure…
- Trial name
- NCT07819591
- Testing
- Paclitaxel Polymeric Micelles, Ivonescimab
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Shaodong Hong
Urothelial Carcinoma, Renal Cell Carcinoma
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types…
- Conditions
- Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer
- Trial name
- NCT03170960
- Testing
- cabozantinib, atezolizumab
- Where
- 124 sites in United States, Australia and 7 more
- Volunteers
- 914 people
- Sponsor
- Exelixis
Extensive Disease Small Cell Lung Cancer
A Multicenter Phase II Trial to Evaluate Rechallenge With Platinum-based Chemotherapy (Carboplatin, Etoposide) for Progression During Tarlatamab Therapy in Relapsed Extensive Disease Small-cell Lung Cancer (SCLC)
The integration of tarlatamab, a bispecific T-cell engager molecule targeting both DLL3 and CD3, into the treatment algorithm for SCLC will substantially improve the prognosis of patients.
- Trial name
- REPLAT (NCT07699237)
- Testing
- Tarlatamab, Carboplatin, Etoposid
- Volunteers
- 54 people
- Sponsor
- University of Cologne
EGFR Mutant Advanced Non-small Cell Lung Cancer, Central Nervous System (CNS) Metastases
A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
This study is a patient-centered, two-group, three-cohort, multi-center, prospective study to further evaluate the survival benefits and safety of zorifertinib as a first-line treatment in EGFRm+ advanced NSCLC patients with CNS…
- Trial name
- NCT07143045
- Testing
- zorifertinib
- Where
- 34 sites in China
- Volunteers
- 800 people
- Sponsor
- Alpha Biopharma (Jiangsu) Co., Ltd.
Non-Small Cell Lung Cancer, Advanced Solid Tumours
Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours
A Phase I, open-label, multicentre, dose-escalation study to investigate the safety, pharmacokinetics and maximum tolerated dose (MTD) of AZD4785 in patients with advanced solid tumours where KRAS may be an important driver of…
- Trial name
- NCT03101839
- Testing
- AZD4785
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 28 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer Stage IIIC, Non-small Cell Lung Cancer Stage IV
Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer
This is a phase 2, pragmatic, 1:1 randomized, open-label study that evaluates risk-adapted, proteomic-guided systemic therapy to improve 12-month progression free survival (PFS) among patients with previously untreated advanced…
- Conditions
- Non-small Cell Lung Cancer Stage IIIC, Non-small Cell Lung Cancer Stage IV, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer Metastatic
- Trial name
- NCT07250477
- Testing
- Systemic (ICI)-based therapy informed by the PROphet CB assay and the CARG-TT assessment., Standard of Care
- Where
- 4 sites in United States
- Volunteers
- 56 people
- Sponsor
- University of California, Davis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.